This brand name is authorized in Nigeria
The drug OFLONIDA contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Ofloxacin
UNII A4P49JAZ9H - OFLOXACIN
|
|
Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination. |
|
2
Ornidazole
UNII 62XCK0G93T - ORNIDAZOLE
|
|
Ornidazole is indicated for the treatment of Bacterial vaginosis. It is effective against Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia (Giardia intestinalis), and also against certain anaerobic bacteria such as Bacteroides and Clostridium spp., Fusobacterium spp., and anaerobic cocci. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01RA09 | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01R Combinations of antibacterials → J01RA Combinations of antibacterials | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NG | Registered Drug Product Database | Identifier(s): B4-2674 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
